Clariane Full Year 2024 Earnings: Revenues In Line With Expectations

Clariane (EPA:CLARI) Full Year 2024 Results

Key Financial Results

• Revenue: €5.28b (up 5.7% from FY 2023).
• Net loss: €30.3m (loss narrowed by 67% from FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clariane Meets Expectations

Revenue was in line with analyst estimates.

In the last 12 months, the only revenue segment was Healthcare Facilities & Services contributing €5.28b. Notably, cost of sales worth €3.15b amounted to 60% of total revenue thereby underscoring the impact on earnings.Explore how CLARI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Healthcare industry in Europe.

Performance of the market in France.

The company's shares are up 32% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Clariane has 3 warning signs (and 2 which are a bit unpleasant) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.